Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
Emilio Besada Bone and Joint Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, Norway Abstract: Treatment of rheumatoid arthritis (RA) was revolutionized during the last decade with the development of new biologic disease-modify...
Published in: | Patient Preference and Adherence |
---|---|
Main Author: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Press
2014
|
Subjects: | |
Online Access: | https://www.dovepress.com/potential-patient-benefit-of-a-subcutaneous-formulation-of-tocilizumab-peer-reviewed-fulltext-article-PPA |
id |
ftdovepress:oai:dovepress.com/17809 |
---|---|
record_format |
openpolar |
spelling |
ftdovepress:oai:dovepress.com/17809 2023-05-15T18:34:54+02:00 Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review Besada,Emilio 2014-08-01 text/html https://www.dovepress.com/potential-patient-benefit-of-a-subcutaneous-formulation-of-tocilizumab-peer-reviewed-fulltext-article-PPA en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/PPA.S34958 https://www.dovepress.com/potential-patient-benefit-of-a-subcutaneous-formulation-of-tocilizumab-peer-reviewed-fulltext-article-PPA info:eu-repo/semantics/openAccess Patient Preference and Adherence Review info:eu-repo/semantics/article 2014 ftdovepress https://doi.org/10.2147/PPA.S34958 2022-12-27T21:44:45Z Emilio Besada Bone and Joint Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, Norway Abstract: Treatment of rheumatoid arthritis (RA) was revolutionized during the last decade with the development of new biologic disease-modifying anti-rheumatic drugs (DMARDs) enabling the targeting of immune cells and cytokines other than tumor necrosis factor (TNF). Subcutaneous formulations of the newer biologic DMARDs facilitate not only patients’ emancipation from the hospital, but reduce both societal and medical costs. Intravenous tocilizumab (TCZ) in RA has an efficacy and safety profile similar to anti-TNF in both the short and long-term. However, TCZ can be administered in monotherapy without loss of efficacy when patients do not tolerate methotrexate or synthetic DMARDs. TCZ is consistently found superior to methotrexate and possibly superior to adalimumab in monotherapy in randomized controlled trials. Subcutaneous administration of TCZ is as effective and safe as its intravenous administration in RA patients during the first year of treatment. Similar to intravenous TCZ, patients’ weight and possibly previous use of anti-TNF influence the efficacy of subcutaneous TCZ. Additionally, combination with synthetic DMARDs seems to expose RA patients to more adverse events independently of its administration route. Pharmacokinetics of different administration routes could potentially lead to differences in efficacy, adverse events, and auto-immunogenicity. The concentration of free TCZ before new TCZ dose (C trough) is higher in the subcutaneous route, while the maximal concentration of free TCZ is higher in the intravenous route. The subcutaneous dosages of TCZ 162 mg every week, and every 2 weeks in RA patients with low body weight (<60 kg) work well. Nevertheless, dosage and intervals of subcutaneous TCZ administration could be adjusted during the course of treatment since 80% of non-Japanese RA patients with usually higher body weight achieved ... Article in Journal/Newspaper Tromsø Arctic University of Norway UiT The Arctic University of Norway Dove Medical Press Arctic Norway Tromsø Patient Preference and Adherence 1051 |
institution |
Open Polar |
collection |
Dove Medical Press |
op_collection_id |
ftdovepress |
language |
English |
topic |
Patient Preference and Adherence |
spellingShingle |
Patient Preference and Adherence Besada,Emilio Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
topic_facet |
Patient Preference and Adherence |
description |
Emilio Besada Bone and Joint Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, Norway Abstract: Treatment of rheumatoid arthritis (RA) was revolutionized during the last decade with the development of new biologic disease-modifying anti-rheumatic drugs (DMARDs) enabling the targeting of immune cells and cytokines other than tumor necrosis factor (TNF). Subcutaneous formulations of the newer biologic DMARDs facilitate not only patients’ emancipation from the hospital, but reduce both societal and medical costs. Intravenous tocilizumab (TCZ) in RA has an efficacy and safety profile similar to anti-TNF in both the short and long-term. However, TCZ can be administered in monotherapy without loss of efficacy when patients do not tolerate methotrexate or synthetic DMARDs. TCZ is consistently found superior to methotrexate and possibly superior to adalimumab in monotherapy in randomized controlled trials. Subcutaneous administration of TCZ is as effective and safe as its intravenous administration in RA patients during the first year of treatment. Similar to intravenous TCZ, patients’ weight and possibly previous use of anti-TNF influence the efficacy of subcutaneous TCZ. Additionally, combination with synthetic DMARDs seems to expose RA patients to more adverse events independently of its administration route. Pharmacokinetics of different administration routes could potentially lead to differences in efficacy, adverse events, and auto-immunogenicity. The concentration of free TCZ before new TCZ dose (C trough) is higher in the subcutaneous route, while the maximal concentration of free TCZ is higher in the intravenous route. The subcutaneous dosages of TCZ 162 mg every week, and every 2 weeks in RA patients with low body weight (<60 kg) work well. Nevertheless, dosage and intervals of subcutaneous TCZ administration could be adjusted during the course of treatment since 80% of non-Japanese RA patients with usually higher body weight achieved ... |
format |
Article in Journal/Newspaper |
author |
Besada,Emilio |
author_facet |
Besada,Emilio |
author_sort |
Besada,Emilio |
title |
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
title_short |
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
title_full |
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
title_fullStr |
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
title_full_unstemmed |
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
title_sort |
potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review |
publisher |
Dove Press |
publishDate |
2014 |
url |
https://www.dovepress.com/potential-patient-benefit-of-a-subcutaneous-formulation-of-tocilizumab-peer-reviewed-fulltext-article-PPA |
geographic |
Arctic Norway Tromsø |
geographic_facet |
Arctic Norway Tromsø |
genre |
Tromsø Arctic University of Norway UiT The Arctic University of Norway |
genre_facet |
Tromsø Arctic University of Norway UiT The Arctic University of Norway |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.2147/PPA.S34958 https://www.dovepress.com/potential-patient-benefit-of-a-subcutaneous-formulation-of-tocilizumab-peer-reviewed-fulltext-article-PPA |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.2147/PPA.S34958 |
container_title |
Patient Preference and Adherence |
container_start_page |
1051 |
_version_ |
1766219899083948032 |